The DOI matches its Crossref record.
Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease
Open accessAbstract
Background —We report the effects of the administration of recombinant fibroblast growth factor-2 (rFGF-2) protein on myocardial perfusion using single photon emission computed tomography imaging in humans with advanced coronary disease. Methods and Results —A total of 59 patients with coronary disease that was not amenable to mechanical revascularization underwent intracoronary (n=45) or intravenous (n=14) administration of rFGF-2 in ascending doses. Changes in perfusion were evaluated at baseline and again at 29, 57, and 180 days after rFGF-2 administration. In this uncontrolled study, perfusion scans were analyzed by 2 observers who were blinded to patient identity and test sequence; scans were displayed in random order, with scans from nonstudy patients randomly interspersed to enhance blinding. Combining all dose groups, a reduction occurred in the per-segment reversibility score (reflecting the magnitude of inducible ischemia) from 1.7±0.4 at baseline to 1.1±0.6 at day 29 ( P <0.001), 1.2±0.7 at day 57 ( P <0.001), and 1.1±0.7 at day 180 ( P <0.001). The 37 patients with evidence of resting hypoperfusion had evidence of improved resting perfusion: their per-segment rest perfusion score of 1.5±0.5 at baseline decreased to 1.0±0.8 at day 29 ( P <0.001), 1.0±0.8 at day 57 ( P =0.003), and 1.1±0.9 at day 180 ( P =0.11). Conclusions —These preliminary data suggest that the administration of rFGF-2 to patients with advanced coronary disease resulted in an attenuation of stress-induced ischemia and an improvement in resting myocardial perfusion; these findings are consistent with a favorable effect of therapeutic angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Simons, M., Annex, B. H., Laham, R. J., Kleiman, N., Henry, T., Dauerman, H., Udelson, J. E., Gervino, E. V., Pike, M., Whitehouse, M. J., et al. (2002) · Circulation · doi:10.1161/hc0802.104407 · Cited by 645
Self-citationFuchs, S., Satler, L. F., Kornowski, R., Okubagzi, P., Weisz, G., Baffour, R., Waksman, R., Weissman, N. J., Cerqueira, M., Leon, M. B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00328-0 · Cited by 419
Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines
Losordo, D. W., & Dimmeler, S. (2004) · Circulation · doi:10.1161/01.cir.0000128595.79378.fa · Cited by 357
Grines, C. L., Watkins, M. W., Mahmarian, J. J., Iskandrian, A. E., Rade, J. J., Marrott, P., Pratt, C., & Kleiman, N. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00988-4 · Cited by 289
The role of fibroblast growth factors in vascular development
Javerzat, S., Auguste, P., & Bikfalvi, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02394-8 · Cited by 266
Metadata
- Authors
- Udelson, J. E., Dilsizian, V., Laham, R. J., Chronos, N., Vansant, J., Blais, M., Galt, J. R., Pike, M., Yoshizawa, C., & Simons, M.
- Venue
- Circulation
- Published
- 2000-10-03
- Volume
- 102
- Issue
- 14
- Pages
- 1605-1610
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2056355686
- Cited by
- 163
- References
- 0
- FWCI
- 17.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease. https://app.cochat.ai/papers/10.1161/01.cir.102.14.1605
- The paper
- Udelson, J. E., Dilsizian, V., Laham, R. J., Chronos, N., Vansant, J., Blais, M., Galt, J. R., Pike, M., Yoshizawa, C., & Simons, M. (2000). Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease. Circulation. https://doi.org/10.1161/01.cir.102.14.1605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.